Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)
This article was originally published in PharmAsia News
Executive Summary
Novartis' lawsuit to gain a patent for a new formulation of Gleevec is the first legal challenge to Section 3(d) of the Indian Patent Act, which seeks to bar "evergreening" by restricting patents for minor improvements to old formulations